コーパス検索結果 (left1)
  通し番号をクリックするとPubMedの該当ページを表示します
  
   1                                              MC3R(hDM/hDM) bone- and adipose tissue-derived mesenchym
     2                                              MC3R(hDM/hDM) impacts nutrient partitioning to generate 
     3                                              MC3R(hDM/hDM) mice do not have increased adipose tissue 
     4                                              MC3R-deficient (MC3R(-)(/)(-)) mice demonstrate increase
     5                                              MC3Rs are expressed in hypothalamic and limbic regions o
  
     7 s, melanocortin-4 (MC4R) and melanocortin-3 (MC3R), are involved in the regulation of satiety and ene
  
  
  
    11  and natural [agouti-related protein (AGRP)] MC3R antagonists but not by the MC4R antagonist Ac-Cys-N
  
  
  
  
    16 at the mouse melanocortin receptors MC1R and MC3R-MC5R and human melanocytes known to express the MC1
  
  
  
  
    21 reopening of the superior mesenteric artery, MC3R-null mice displayed a higher degree of plasma extra
    22 was used to examine the associations between MC3R polymorphisms and the measures of energy balance.  
    23 nce of a tonic inhibitory signal provided by MC3R in the mesenteric microcirculation of the mouse, ac
  
  
  
  
    28  useful for in vivo studies to differentiate MC3R vs MC4R physiological roles in animal models, such 
  
  
    31 rphisms in the melanocortin-3 receptor gene (MC3R) coding sequence, C17A and G241A, has been reported
    32 le-mutant (C17A+G241A) human (MC3R(hDM/hDM)) MC3R, that MC3R(hDM/hDM) have greater weight and fat mas
    33 the intracellular cAMP accumulation in human MC3R, MC4R, and MC5R revealed that the native peptide sh
  
  
    36 /hWT)) and double-mutant (C17A+G241A) human (MC3R(hDM/hDM)) MC3R, that MC3R(hDM/hDM) have greater wei
    37 we replace murine Mc3r with wild-type human (MC3R(hWT/hWT)) and double-mutant (C17A+G241A) human (MC3
  
  
    40 0), but not Arg(7), result in an increase in MC3R selectivity over the MC4R and MC5R and only agonist
  
  
    43 -MSH led to accumulation of cAMP, indicating MC3R receptor functionality: this effect was blocked by 
  
  
  
  
  
  
  
  
    52 n 2 (FABP2), melanocortin 2 receptor (MC2R), MC3R, PPARG coactivator 1 alpha (PPARGC1A), and tumor ne
  
    54 dy is to determine the structural aspects of MC3R responsible for ligand binding and receptor signali
    55 ever, the specific molecular determinants of MC3R responsible for ligand binding and receptor signali
  
  
  
  
  
  
    62  mutations impairing the function of MC4R or MC3R were associated with severe obesity in North Americ
    63 ectivity (223- to 467-fold) toward MC4R over MC3R and MC5R receptor subtypes without compromising ago
    64  MC4R, was more than 200-fold selective over MC3R, and had a good pharmacokinetic profile in mice, in
  
  
    67  and antagonists of melanocortin-3 receptor (MC3R) and MC4R point to the importance of the CNS melano
    68 ortin (POMC) at the melanocortin 3 receptor (MC3R) and melanocortin 4 receptor (MC4R) and has been pr
  
    70 ogical roles of the melanocortin-3 receptor (MC3R) is lacking because of the limited number of known 
  
    72 lated receptor, the Melanocortin-3 receptor (MC3R), could also be a cause of severe human obesity.   
  
  
    75 ous antagonist of the melanocortin receptors MC3R and MC4R found in the hypothalamus and exhibits pot
    76 ous antagonist of the melanocortin receptors MC3R and MC4R found in the hypothalamus and exhibits pot
  
  
  
    80 melanocortin-3 and melanocortin-4 receptors (MC3R, MC4R) are involved in the metabolic and food intak
  
  
    83 y expressed melanocortin-3 and -4 receptors (MC3R/MC4R) have been studied as possible targets for wei
  
    85 ogical treatment of animals with a selective MC3R agonist ([D-Trp(8)]-gamma-melanocyte-stimulating ho
    86 lpha-MSH, melanotan II (MTII), and selective MC3R or MC4R agonists were all inhibitory, reducing the 
    87 e of the recent description of the selective MC3R agonist [d-Trp(8)]-gamma-melanocyte-stimulating hor
    88 ata support the development of the selective MC3R agonist [d-Trp(8)]-gamma-MSH for the treatment of i
  
  
    91 from identified neurons, we demonstrate that MC3R and MC4R agonists depolarize arcuate POMC neurons a
    92 C17A+G241A) human (MC3R(hDM/hDM)) MC3R, that MC3R(hDM/hDM) have greater weight and fat mass, increase
  
  
  
    96  native peptide shows potent activity at the MC3R (EC(50) = 5.9 nM) and is about 50-100-fold selectiv
  
  
    99  1 order of magnitude (IC(50) = 6 nM) at the MC3R compared with that of the natural molecule and an i
  
   101 10-fold more potent (IC(50) = 8.8 nM) at the MC3R compared with the native peptide but lacks subtype 
  
   103 melanocortin neurons selectively express the MC3R, which provides a neuroanatomical basis for a dual-
   104 highly selective antagonist analogue for the MC3R (560-fold vs the hMC4R and about 3000-fold vs the h
   105 ly, the DTyr(1) peptide is selective for the MC3R (EC(50) = 12 nM) by 40-200-fold compared with the M
   106 50) = 11 nM) analogues are selective for the MC3R by 1 and 2 orders of magnitude compared with the MC
   107 ecule and an increase in selectivity for the MC3R by 2 orders of magnitude compared with the activity
  
  
  
   111 gonist ligand for the hMC5R (560-fold vs the MC3R and 1000-fold vs the MC4R); (2) compound 7, Ac-c[Cy
  
  
   114 viously reported children homozygous for two MC3R sequence variants (C17A+G241A) have greater fat mas
   115 he His(6) position can determine MC4R versus MC3R agonist selectivity and that chemically nonreactive
   116 tified a new and novel >200-fold MC4R versus MC3R selective peptide Tyr-c[Asp-D-Phe-Arg-Trp-Asn-Ala-P
  
   118  metabolism involves divergent pathways; VMH MC3R signaling improves metabolic homeostasis but does n
  
  
   121 ment of 1, a potent, selective (1184-fold vs MC3R, 350-fold vs MC5R), small-molecule agonist of the M
   122 pitous discovery of nine compounds that were MC3R agonists (EC50 < 1000 nM) and MC4R antagonists (5.7
  
  
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。